Advancing Education on Biosimilars Act of 2021
Summary
Advancing Education on Biosimilars Act of 2021 This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.) The FDA may also maintain and operate a website to provide educational materials about biological products.
Bill status
in committee
1 of 4 stages cleared
Introduction
Mar 2021
Committee Review
Floor Vote
President
Introduced Mar 12, 2021
Last action Mar 16, 2021
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
3
Key actions
0
Committee
2
Mar 16, 2021
Committee
Referred to the Subcommittee on Health.
lower
Mar 12, 2021
Committee
Referred to the House Committee on Energy and Commerce.
lower
Mar 12, 2021
Introduced
Introduced in House
lower
1 primary · 1 co-sponsor
Sponsors
Ask Maddy
·
AI policy assistant
Ask Maddy about HR 1873
Scope: US
Hi! I can help you understand HR 1873. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline